Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: Comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR Trial

William Insull, Jalal K. Ghali, David R. Hassman, Joseph W. Yčas, Sanjay K. Gandhi, Elinor Miller

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

OBJECTIVE: To evaluate attainment of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III low-density lipoprotein cholesterol (LDL-C) goal of less than 100 mg/dl with statin treatments in managed care patients at high fish for coronary heart disease. PATIENTS AND METHODS: In a randomised, open-label, multicenter trial (SOLAR [Satisfying Optimal LDL-C ATP III goals with Rosuvastatin]) performed at 145 US clinical centers from June 5, 2002 to July 12, 2004, high-risk men and women in a managed care population received typical starting doses of rosuvastatin (10 mg/d), atorvastatin (10 mg/d), or simvastatin (20 mg/d) for 6 weeks. Those who did not meet the LDL-C target of less than 100 mg/dL at 6 weeks had their dose titrated (doubled), and all patients were followed up for another 6 weeks. RESULTS: A total of 1632 patients were randomized to 1 of the 3 treatment regimens. After 6 weeks, 65% of patients taking rosuvastatin reached the LDL-C target of less than 100 mg/dL vs 41% with atorvastatin and 39% with simvastatin (P<.001 vs rosuvastatin for both). After 12 weeks, 76% of patients taking rosuvastatin reached the LDL-C target of less than 100 mg/dL vs 58% with atorvastatin and 53% with simvastatin (P<.001 vs rosuvastatin for both). Reductions in the LDL-C level, total cholesterol level, non-high-denslty lipoprotein cholesterol (non-HDL-C) level, and non-UDL-C/HDL-C ratio were significantly greater with rosuvastatin at both 6 and 12 weeks compared with the other statins. Adverse events were similar in type and frequency in all treatment groups, and only 3% of all patients discontinued treatment because of adverse events, No myopathy was observed, no clinically important impact on renal function was attributed to study medications, and clinically important increases in serum transaminases were rare. CONCLUSION: In a managed care population, 10 mg of rosuvastatin treatment resulted in more patients reaching the NCEP ATP III LDL-C goal compared with 10 mg of atorvastatin and 20 mg of simvastatin, potentially reducing the need for titration visits.

Original languageEnglish (US)
Pages (from-to)543-550
Number of pages8
JournalMayo Clinic Proceedings
Volume82
Issue number5
DOIs
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: Comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR Trial'. Together they form a unique fingerprint.

Cite this